Upregulation of miR-2861 and miR-451 expression in papillary thyroid carcinoma with lymph node metastasis

Medical Oncology

Volumn 30, Issue 2, 2013, Pages

  Wang, Zhihong ^a   Zhang, Hao ^a   Zhang, Ping ^a   Li, Jing ^a   Shan, Zhongyan ^a   Teng, Weiping ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

Lymph node metastasis; MicroRNA; Papillary thyroid carcinoma (PTC)

Indexed keywords

MICRORNA; MICRORNA 1202; MICRORNA 193B; MICRORNA 2861; MICRORNA 451; MICRORNA 542 5P; MICRORNA 664; MICRORNA LET 7I; UNCLASSIFIED DRUG; MIRN2861 MICRORNA, HUMAN; MIRN451 MICRORNA, HUMAN;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENE EXPRESSION; GENETIC ASSOCIATION; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MICROARRAY ANALYSIS; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDY; RNA ISOLATION; THYROID CARCINOMA; UPREGULATION; ADOLESCENT; CARCINOMA; CLUSTER ANALYSIS; GENETICS; METABOLISM; MIDDLE AGED; NONPARAMETRIC TEST; PATHOLOGY; REPRODUCIBILITY; THYROID TUMOR;

ADOLESCENT; ADULT; AGED; CARCINOMA; CLUSTER ANALYSIS; FEMALE; HUMANS; LYMPHATIC METASTASIS; MALE; MICRORNAS; MIDDLE AGED; REAL-TIME POLYMERASE CHAIN REACTION; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; STATISTICS, NONPARAMETRIC; THYROID NEOPLASMS; UP-REGULATION;

EID: 84876287870     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-013-0577-9     Document Type: Article

References (21)

1. Ito Y, Higashiyama T, Takamura Y, Miya A, Kobayashi K, Matsuzuka F, et al. Risk factors for recurrence to the lymph node in papillary thyroid carcinoma patients without preoperatively detectable lateral node metastasis: validity of prophylactic modified radical neck dissection. World J Surg. 2007;31(11):2085-91.
2. Xing M. BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. Endocr Rev. 2007;28(7):742-62.
3. Lim YS, Lee JC, Lee YS, Lee BJ, Wang SG, Son SM, et al. Lateral cervical lymph node metastases from papillary thyroid carcinoma: predictive factors of nodal metastasis. Surgery. 2011;150(1):116-21.
4. Calin GA, Liu CG, Sevignani C, Ferracin M, Felli N, Dumitru CD, et al. MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias. Proc Natl Acad Sci USA. 2004;101(32):11755-60.
5. Jiang J, Lee EJ, Gusev Y, Schmittgen TD. Real-time expression profiling of microRNA pre-cursors in human cell lines. Nucleic Acids Res. 2005;33(17):5394-403.
6. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, et al. MicroRNA expression profiles classify human cancers. Nature. 2005;435(7043):834-8.
7. Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA. 2006;103(7):2257-61.
8. Chou CK, Chen RF, Chou FF, Chang HW, Chen YJ, Lee YF, et al. miR-146b is highly expressed in adult papillary thyroid carcinomas with high risk features including extrathyroidal invasion and the BRAF (V600E) mutation. Thyroid. 2010;20(5):489-94.
9. Yip L, Kelly L, Shuai Y, Armstrong MJ, Nikiforov YE, Carty SE, et al. MicroRNA signature distinguishes the degree of aggressiveness of papillary thyroid carcinoma. Ann Surg Oncol. 2011;18(7):2035-41.
10. Zhou YL, Liu C, Dai XX, Zhang XH, Wang OC. Overexpression of miR-221 is associated with aggressive clinicopathologic characteristics and the BRAF mutation in papillary thyroid carcinomas. Med Oncol. 2012;29(5):3360-6.
11. Chou CK, Yang KD, Chou FF, Huang CC, Lan YW, Lee YF, et al. Prognostic implications of miR-146b expression and Its functional role in papillary thyroid carcinoma. J Clin Endocrinol Metab. 2013;98(2):E196-205.
12. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2 (-Delta Delta C (T)) Method. Methods. 2001;25(4):402-8.
13. Konishi H, Ichikawa D, Komatsu S, Shiozaki A, Tsujiura M, Takeshita H, et al. Detection of gastric cancer-associated microRNAs on microRNA microarray comparing pre- and post-operative plasma. Br J Cancer. 2012;106(4):740-7.
14. Brenner B, Hoshen MB, Purim O, David MB, Ashkenazi K, Marshak G, et al. MicroRNAs as a potential prognostic factor in gastric cancer. World J Gastroenterol. 2011;17(35):3976-85.
15. Nan Y, Han L, Zhang A, Wang G, Jia Z, Yang Y, et al. MiRNA-451 plays a role as tumor suppressor in human glioma cells. Brain Res. 2010;1359:14-21.
16. Sand M, Skrygan M, Sand D, Georgas D, Hahn SA, Gambichler T, et al. Expression of microRNAs in basal cell carcinoma. Br J Dermatol. 2012;167(4):847-55.
17. Gimm O, Rath FW, Dralle H. Pattern of lymph node metastases in papillary thyroid carcinoma. Br J Surg. 1998;85(2):252-4.
18. Fabbri M, Ivan M, Cimmino A, Negrini M, Calin GA. Regulatory mechanisms of microRNAs involvement in cancer. Expert Opin Biol Ther. 2007;7(7):1009-19.
19. Kitano M, Rahbari R, Patterson EE, Steinberg SM, Prasad NB, Wang Y, et al. Evaluation of candidate diagnostic microRNAs in thyroid fine-needle aspiration biopsy samples. Thyroid. 2012;22(3):285-91.
20. Shen R, Liyanarachchi S, Li W, Wakely PE Jr, Saji M, Huang J, et al. MicroRNA signature in thyroid fine needle aspiration cytology applied to "atypia of undetermined significance" cases. Thyroid. 2012;22(1):9-16.
21. Keutgen XM, Filicori F, Crowley MJ, Wang Y, Scognamiglio T, Hoda R, et al. A panel of four miRNAs accurately differentiates malignant from benign indeterminate thyroid lesions on fine needle aspiration. Clin Cancer Res. 2012;18(7):2032-8.